PMID- 24721396
OWN - NLM
STAT- MEDLINE
DCOM- 20140715
LR  - 20181202
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 30
IP  - 4
DP  - 2014 Apr
TI  - [Effect of PLGA nanoparticles conjugated with anti-OX40/anti-AFP mAbs on 
      cytotoxicity of CTL cells against hepatocellular carcinoma].
PG  - 337-41
AB  - OBJECTIVE: To evaluate the effect of anti-OX40 and anti-AFP antibodies conjugated 
      onto poly(DL-lactide-co-glycolide)-nanoparticles (PLGA-NPs) on the cytotoxic 
      activity of AFP158-166; -specific cytotoxic T lymphocyte (CTL) against 
      hepatocellular carcinoma cells in vitro. METHODS: PLGA-NPs were prepared by 
      oil-in-water single emulsion solvent evaporation method and covalently conjugated 
      with anti-OX40 and anti-AFP monoclonal antibodies. Scanning electron microscopy 
      (SEM) was utilized for the characterization of the surface morphology and 
      estimation of the size of the PLGA-NPs. The mean diameter and zeta potential of 
      the nanoparticles were measured by dynamic light scattering (DLS) performed in a 
      Zetasiser Nano Series ZEN3600. Antibody conjugation efficiency was determined 
      using bicinchoninic acid (BCA) protein assay. Dendritic cells (DCs) were induced 
      from human peripheral blood mononuclear cells (PBMCs) in the presence of GM-CSF 
      and IL-4, and loaded with AFP158-166; peptide to generate AFP-specific CTL 
      (CTL/AFP158-166;). WST-1, ELISA and lactate dehydrogenase (LDH) methods were 
      respectively used to examine the effects of the anti-OX40/anti-AFP-NPs on 
      CTL/AFP158-166; proliferation, IL-2 and IFN-gamma production, and cytotoxicity 
      against the tumor cells. RESULTS: The obtained nanoparticles were found to be of 
      regular spherical shape and the smooth surface with an average diameter of 
      (300+/-42) nm and a negative zeta potential of -(25.12+/-5.34) mV. Approximately 100 
      mug antibodies were conjugated to every milligram of the nanoparticles with a 
      conjugation efficiency of about 25% as estimated by BCA protein assay. 
      Proliferation and activation analysis revealed that anti-OX40/anti-AFP mAb-NPs 
      significantly induced CTL proliferation and the secretion of IL-2 and IFN-gamma. The 
      cytotoxicity assay showed that anti-OX40/anti-AFP-NPs markedly enhanced 
      CTL/AFP158-166; specific killing on HepG2 cells but had no obvious effect on 
      SMMC-7721 cells. CONCLUSION: Anti-OX40 mAb and anti-AFP mAb conjugated to 
      PLGA-NPs could stimulate CTL/AFP158-166; cell proliferation and cytokine 
      production as well as enhancing their specific killing on AFP-positive 
      hepatocellular carcinoma cells.
FAU - Chen, Mingshui
AU  - Chen M
AD  - Teaching Hospital of Fujian Medical University, Laboratory of Immuno-Oncology, 
      Fujian Provincial Tumor Hospital, Fuzhou 350014; Fujian Provincial Key Laboratory 
      of Translational Cancer Medicine, Fuzhou 350014, China.
FAU - Ouyang, Haichao
AU  - Ouyang H
AD  - Teaching Hospital of Fujian Medical University, Laboratory of Immuno-Oncology, 
      Fujian Provincial Tumor Hospital, Fuzhou 350014, China.
FAU - Zhou, Shanyong
AU  - Zhou S
AD  - State Key Laboratory of Structural Chemistry, Fujian Institute of Research on 
      Structure of Matter, Chinese Academy of Sciences, Fuzhou 350000, China.
FAU - Li, Jieyu
AU  - Li J
AD  - Teaching Hospital of Fujian Medical University, Laboratory of Immuno-Oncology, 
      Fujian Provincial Tumor Hospital, Fuzhou 350014; Fujian Provincial Key Laboratory 
      of Translational Cancer Medicine, Fuzhou 350014, China.
FAU - Ye, Yunbin
AU  - Ye Y
AD  - Teaching Hospital of Fujian Medical University, Laboratory of Immuno-Oncology, 
      Fujian Provincial Tumor Hospital, Fuzhou 350014; Fujian Provincial Key Laboratory 
      of Translational Cancer Medicine, Fuzhou 350014, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - 0 (AFP protein, human)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Interleukin-2)
RN  - 0 (Receptors, OX40)
RN  - 0 (alpha-Fetoproteins)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Antibodies, Monoclonal/chemistry/*immunology
MH  - Carcinoma, Hepatocellular/*immunology/pathology/therapy
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Humans
MH  - Immunotherapy
MH  - Interferon-gamma/metabolism
MH  - Interleukin-2/metabolism
MH  - Lactic Acid/*chemistry
MH  - Liver Neoplasms/immunology/pathology/therapy
MH  - Nanoparticles/*chemistry
MH  - Polyglycolic Acid/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Receptors, OX40/*immunology
MH  - Surface Properties
MH  - T-Lymphocytes, Cytotoxic/*immunology/metabolism
MH  - alpha-Fetoproteins/*immunology
EDAT- 2014/04/12 06:00
MHDA- 2014/07/16 06:00
CRDT- 2014/04/12 06:00
PHST- 2014/04/12 06:00 [entrez]
PHST- 2014/04/12 06:00 [pubmed]
PHST- 2014/07/16 06:00 [medline]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 Apr;30(4):337-41.